MERCK & CO., INC. |
Market Closed -
Other stock markets
|
After market 06:00:01 pm | |||
| 127 USD | +0.09% |
|
128.6 | +1.26% |
Presenter SpeechKenneth Frazier (Executives)Good morning, ladies and gentlemen, and welcome to...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
06:30am
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
127
USD
Average target price
137.6
USD
Spread / Average Target
+8.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.49% | 321B | |
| +25.61% | 672B | |
| +25.87% | 570B | |
| -5.24% | 360B | |
| +8.28% | 300B | |
| +7.09% | 217B | |
| -9.12% | 204B | |
| +5.01% | 199B | |
| -8.75% | 149B | |
| -5.21% | 147B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Transcript : Merck & Co. Inc. - Shareholder/Analyst Call
